Fulcrum Therapeutics posts new investor presentation

Fulcrum Therapeutics, Inc. furnished an updated corporate presentation dated August 28, 2025 that may be used at conferences and investor meetings.

Rhea-AI Filing Summary

Fulcrum Therapeutics, Inc. furnished an updated corporate presentation dated August 28, 2025 that may be used at conferences and investor meetings. The presentation is available in the Events and Presentations section of the company’s website and is attached as Exhibit 99.1. Fulcrum specifies that this material is provided under Regulation FD and is considered “furnished” rather than “filed,” which means it is not automatically subject to certain Exchange Act liabilities or incorporated into other securities law filings unless specifically referenced.

8-K Event Classification

2 items: 7.01, 9.01

2 items

Item 7.01 Regulation FD Disclosure Disclosure

Material non-public information disclosed under Regulation Fair Disclosure, often investor presentations or guidance.

Item 9.01 Financial Statements and Exhibits Exhibits

Financial statements, pro forma financial information, or exhibit attachments filed with this report.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Fulcrum Therapeutics (FULC) disclose in this 8-K?

Fulcrum Therapeutics disclosed that it made available an updated corporate presentation dated August 28, 2025, which may be used for conferences and investor meetings and is furnished as Exhibit 99.1.

Where can investors find Fulcrum Therapeutics’ updated August 28, 2025 corporate presentation?

The updated corporate presentation can be found in the “Events and Presentations” section of Fulcrum Therapeutics’ website and is also attached as Exhibit 99.1.

How is the new Fulcrum Therapeutics (FULC) corporate presentation treated under securities laws?

The company states that the information in Item 7.01, including Exhibit 99.1, is furnished under Regulation FD and is not deemed “filed” under Section 18 of the Exchange Act or incorporated into other filings unless specifically referenced.

Which exhibit in this Fulcrum Therapeutics 8-K contains the updated presentation?

Exhibit 99.1 is the corporate presentation dated August 28, 2025. Exhibit 104 is the cover page interactive data file embedded within the Inline XBRL document.

Who signed this Fulcrum Therapeutics (FULC) 8-K?

The report was signed on behalf of Fulcrum Therapeutics, Inc. by Alex C. Sapir, President and Chief Executive Officer, dated August 28, 2025.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding 8-K Material Events →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 08/28/2025 - 10:41 AM Learn about SEC filing dates

false000168058100016805812025-08-282025-08-28

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): August 28, 2025

Fulcrum Therapeutics, Inc.

(Exact name of registrant as specified in its charter)

Delaware			001-38978	47-4839948
(State or other jurisdiction of incorporation)			(Commission File Number)	(IRS Employer Identification No.)
26 Landsdowne Street
Cambridge, Massachusetts				02139
(Address of principal executive offices)				(Zip Code)

Registrant’s telephone number, including area code: (617) 651-8851

N/A

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbol(s)		Name of each exchange on which registered
Common stock, par value $0.001 per share		FULC		Nasdaq Global Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 7.01 Regulation FD Disclosure.

On August 28, 2025, Fulcrum Therapeutics, Inc., or Fulcrum, made available an updated corporate presentation that may be used in connection with presentations at conferences and investor meetings, which can be found in the “Events and Presentations” section on the Company’s website. The corporate presentation is furnished as Exhibit 99.1 to this Current Report on Form 8-K and incorporated by reference in this Item 7.01.

The information in this Item 7.01, including Exhibit 99.1 attached hereto, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or the Exchange Act, or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits

99.1+	Corporate Presentation Dated August 28, 2025
104	Cover Page Interactive Data File (embedded within the Inline XBRL document)

+ Furnished herewith.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

			FULCRUM THERAPEUTICS, INC.
Date:	August 28, 2025	By:	/s/ Alex C. Sapir
			Name: Alex C. Sapir Title: President and Chief Executive Officer